Biosyntia Recieves Investment for a Bio-based Vitamin Production Platform
News May 27, 2015
“Biosyntia is built on a unique technology platform which holds significant promise to rapidly deliver cost efficient production of fine chemicals by sustainable fermentation processes," says Søren Møller Managing Investment Director Novo Seeds.
Cell factory development is laborious and often requires interrogation of many variants in order to identify the optimal cells. Biosyntia’s cell factory development platform enables the company to benefit from ultra-high throughput screening through a process called synthetic selection.
“In essence, Biosyntia burns down the haystack rather than looking for the needle one straw at a time”, says co-founder and technology co-inventor Hans Genee.
Biosyntia first focus area is bio-based production of vitamins for the food and feed industry. The industrial production of vitamins are today mainly based on chemical synthesis and there is a clear need and consumer demand in the market for transitioning the chemically based production methods to more sustainable and cost effective processes.
“Our goal is to disrupt the vitamin market by delivering more sustainable and healthy vitamins. We are establishing a broad technology platform and focus on using this platform to achieve bio-based vitamin production” says co-founder and DTU professor Morten Sommer.
A key factor for success is to bring the production yield of bio-based processes up to levels comparable to existing chemical processes.
“In conjunction with the financing Biosyntia has entered a strategic collaboration with the Center for Biosustainability, at The Technical University of Denmark to gain access to complementary cell factory development technologies. If there are anyone in the world who can meet the challenging yield requirements in this project, it is this young and highly skilled team” says Henrik Dalbøge, Chairman of Biosyntia and former head of Chr. Hansen’s Human Health and Nutrition division.
Biosyntia is one of the region's emerging start-ups aiming to deliver sustainable and bio-based solutions based on the extensive commercial experience and strong research based in Denmark. However, in a competitive industry the outlook must be global:
“We invest worldwide and only in the companies with unique differentiators and competitive edge. We believe that Biosyntia has the potential to build a world leading synthetic biology platform and accordingly can attract international strategic partners and investors”, says Søren Carlsen, Managing Partner of Novo Ventures and Novo Seeds. Søren Møller and Søren Carlsen will join the Board of Biosyntia.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018